FDA clears Roche's Gazyva as first-ever treatment for primary membranous nephropathy
Roche's Gazyva/Gazyvaro just became the first and only FDA-approved therapy for primary membranous nephropathy, a rare autoimmune kidney disease that can end in kidney failure. In the phase III MAJESTY trial, 36.1% of patients on the drug hit complete remission of proteinuria at two years, versus 5.7% on tacrolimus.
- 6 sources report it: finance.yahoo.com, rttnews.com, biospace.com, pharmexec.com and 2 more.
- The source published it on Nov 15, 2026 at 10:01 PM.
Nothing open. Every check passed.
The FDA has approved Gazyva/Gazyvaro (obinutuzumab) for adults with primary membranous nephropathy who are at risk of disease progression, clearing it to induce remission of proteinuria. Roche announced the green light from Basel on 16 November 2026. It is the first and only therapy approved for the disease, and it arrives after the FDA had already handed the drug Breakthrough Therapy Designation.
The decision rides on the phase III MAJESTY study, which hit its primary endpoint. At 104 weeks, 36.1% of adults on Gazyva/Gazyvaro achieved complete remission of proteinuria, against 5.7% on tacrolimus — an adjusted difference of 31.1% (95% CI: 18.2 to 44.0; p<0.001). The drug also won on overall remission at week 104, at 50% versus 12.9% (adjusted difference 37.8%; 95% CI: 23.9 to 51.8), and on complete remission at week 76, at 36.1% versus 8.6% (adjusted difference 27.4%; 95% CI: 13.4 to 39.8).
Safety held up, matching the drug's well-characterised profile with no new signals flagged. Levi Garraway, Roche's chief medical officer and head of global product development, framed the win around the biology: targeting B cells addresses a critical underlying driver of the disease. With the approval, he said, Roche is turning decades of antibody engineering into tangible outcomes for patients with immune-mediated kidney diseases.
The stakes are real. Primary membranous nephropathy is a rare, chronic autoimmune disease, and up to 30% of untreated patients slide into kidney failure within a decade. MAJESTY data landed as a late-breaking oral presentation at the 63rd European Renal Association Congress in June 2026 and were published in the New England Journal of Medicine. Roche is now filing with other regulators, including the European Medicines Agency.
TopicsRoche · Gazyva · Gazyvaro · obinutuzumab · FDA · Levi Garraway · tacrolimus · European Medicines Agency
Written by AI from verified reporting. Not financial advice.

